⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
EcoVadis and leading industry organizations launch the 'Retail Impact Initiative'
prnewswire.com
JNJ
UL
JPM
DigiCert Research Reveals Major Certificate Visibility Blind Spot for Enterprises
globenewswire.com
MSFT
GOOG
AMZN
IBM
ORCL
CSCO
DELL
HPQ
INTC
QCOM
NVDA
AMD
AVGO
MU
AMAT
LRCX
KLAC
ADI
TXN
NXPI
MRVL
SNPS
CDNS
ADSK
CRM
ACN
INFY
SAP
PANW
CRWD
OKTA
FTNT
DDOG
NOW
MCHP
ON
LULU
BBY
COST
HD
LOW
TJX
MDT
AMGN
GILD
BMY
PFE
MRK
JNJ
ABBV
LLY
BIIB
REGN
VRTX
AZN
SNOW
SMCI
PLTR
AI
GOOGL
Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight
globenewswire.com
PFE
JNJ
AMRX
BOLT
BIIB
Radiation Detection, Monitoring & Safety Market worth $5.68 billion by 2031 | MarketsandMarkets™
prnewswire.com
MDT
JNJ
CNMD
BSX
COO
ZBH
STC
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm
globenewswire.com
JNJ
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
prnewswire.com
JNJ
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
prnewswire.com
JNJ
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
prnewswire.com
JNJ
New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
prnewswire.com
JNJ
FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
prnewswire.com
JNJ